LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

Home・Elenco Azioni・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

92.77 1.3

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

89.52

Massimo

93.23

Metriche Chiave
By Trading Economics
Entrata	-8.1M -56M
Vendite	2.9M 60M
EPS	-0.83
Margine di Profitto	-92.559
Dipendenti	414
EBITDA	-9.7M -52M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+49.61% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	301M 6.2B
Apertura precedente	91.47
Chiusura precedente	92.77

Notizie sul Sentiment di mercato

By Acuity

68%

32%

301 / 344 Classifica in Healthcare

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 mag 2026, 22:47 UTC

Utili

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mag 2026, 20:45 UTC

Utili

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mag 2026, 23:31 UTC

Discorsi di Mercato

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mag 2026, 23:17 UTC

Discorsi di Mercato

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mag 2026, 23:02 UTC

Discorsi di Mercato

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mag 2026, 22:37 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mag 2026, 21:12 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mag 2026, 21:00 UTC

Utili

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mag 2026, 20:57 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:55 UTC

Utili

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

28 mag 2026, 20:48 UTC

Azioni calde

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mag 2026, 20:34 UTC

Utili

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mag 2026, 20:31 UTC

Utili

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mag 2026, 20:28 UTC

Utili

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mag 2026, 20:26 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Membership Fees $1.37B

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Net Sales $69.15B

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Same-Store Sales Up 9.8% >COST

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

49.61% in crescita

Previsioni per 12 mesi

Media 136.77 USD 49.61%

Alto 158 USD

Basso 105 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

301 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.